Theralase Technologies Inc. V.TLT

PP and BTD which one will come first?

[managementfirst]

Given now TLT already submitted pre BTD application, FDA will say OK in April, then TLT will submit formal application in May, and will get BTD in June.

TLT has no cash to June, PP must come first, propably in April.

[Oilminerdeluxe]

Theralase® will be hosting a conference call on Wednesday April 3rd, 2024 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st , 2023. Questions are welcome; to ensure we have time to review and answer them during the call, please send them in advance to [e-mail].

[Oilminerdeluxe]

To date, Study II has provided the primary study treatment for 63 patients, with new patients being enrolled in 2Q2024. So new patients are incoming

[Oilminerdeluxe]

The Company plans to resubmit the pre-BTD submission to the FDA in 2Q2024 for FDA review of these clarifications. Once the pre-BTD submission has been accepted by the FDA, the Company will compile a BTD submission for review by the FDA in support of the grant of a BTD approval.

[99942Apophis]

Administration expenses 1.8M, why hasn't the top management personnel taken a reduced salary voluntarily to reduce that cost? Very disappointing year end information, I think I will sell a portion of my holdings,  glta.

[Lesalpes29]

Good question Apophis. Pre-BTD is pushed again? An other PP is a sure thing and problably more than one at this rythm. GL

[Donein25]

This doesn't sound like further PPs to me. Sounds like they will announce issuance of debt. Their goal all along has been to raise enough cash to meet the requirements of a base shelf: 12 months of operating expenses in cash reserve. PPs  are not getting them there. Read Christina's comment re base shelf.  Personally I would rather they issue debt than issue more shares to pay

[Eoganacht]

Interesting. Thanks Donein25.

[DeathXray33]

@>1.320 mil. I'm buying more Thursday & Friday. Farewell.

[Gooseybear]

I agree with disappointing increase in management financial gain and reduced research and development costs. Should be inverse. Was thinking about buying more based on PR release the other day about participating in upcoming urology forum in the US but won't be now.

[managementfirst]

and delayed again. They said will submit Pre BTD in 1Q, but now in 2Q.

[Lesalpes29]

November 29th 2023 : The Company plans to resubmit the pre-BTD submission to the FDA in early 1Q2024 for FDA review of these clarifications. Once the pre-BTD submission has been accepted by the FDA, the Company plans to compile a BTD submission for review by the FDA in support of the grant of a BTD approval in 1Q2024. One day we wiil have it. GL